Panagora Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Panagora Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,640	Closed	-$25K	–	2454
2018 Q1	$25K	Sell	1,640 -15,061	-90%	-$235K	﹤0.01%	2179
2017 Q4	$261K	Sell	16,701 -9,309	-36%	-$124K	﹤0.01%	1584
2017 Q3	$289K	Hold	26,010	–	–	﹤0.01%	1537
2017 Q2	$239K	Sell	26,010 -72,273	-74%	-$603K	﹤0.01%	1585
2017 Q1	$840K	Buy	98,283 +42,777	+77%	+$390K	﹤0.01%	1214
2016 Q4	$594K	Buy	+55,506	New	+$671K	﹤0.01%	1382

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Panagora Asset Management's STML Position: Q2 2018 in Review

Panagora Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 1,640 shares — an estimated $25K sold.

Panagora Asset Management first reported a position in STML in Q4 2016 and held it in 6 quarters. The position peaked at $840K in Q1 2017. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

Panagora Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Panagora Asset Management sold 1,640 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $25K.
Panagora Asset Management first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 6 quarters.
Panagora Asset Management's Stemline Therapeutics, Inc. position peaked at $840K in Q1 2017.
91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on Panagora Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.